IP Library Granted Patent US 10,722,559
Granted Patent B2
US 10,722,559 · App. 15/503,223 · Granted Jul 28, 2020

Mannose-6-phosphate bearing peptides fused to lysosomal enzymes

Inventors: Michael F. Concino (Lexington, MA); Bettina Strack-Logue (Lexington, MA); Muthuraman Meiyappan (Lexington, MA); Angela W. Norton (Lexington, MA); Bohong Zhang (Lexington, MA); Andrea Iskenderian (Lexington, MA); Lieh Yoon Low (Lexington, MA); Dianna Lundberg (Lexington, MA); Alla Romashko (Lexington, MA); Hicham Naimy (Lexington, MA)
Assignee: Shire Human Genetic Therapies, Inc.
A61K38/47A61K38/1709A61K38/204A61K38/30A61K38/43C07K14/4703C07K14/4705C07K14/5412C07K14/65C12N9/1288C12Y207/08017C07K2319/06C12Y302/0105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,722,559
App. No.
15/503,223
Granted
Jul 28, 2020
Kind
B2
Abstract

A targeted therapeutic including a lysosomal enzyme and a lysosomal targeting moiety that is a peptide containing at least one N-linked glycosylation site. Methods of producing the targeted therapeutic may include nucleotide acids encoding the same and host cells co-expressing GNPT. Pharmaceutical compositions comprising the targeted therapeutic and methods of using the same to treat a lysosomal storage disease.

Claims (20)

1. A nucleic acid encoding a targeted therapeutic fusion protein comprising:

a lysosomal enzyme, and

a lysosomal targeting moiety,

wherein the lysosomal targeting moiety is a prosaposin peptide comprising an amino acid sequence of SEQ ID NO: 4, containing at least one N-linked glycosylation site, and

wherein the fusion protein, once administered in vivo, results in reduced lysosomal storage.

2. A vector comprising the nucleic acid sequence of claim 1 .

3. A host cell comprising the vector of claim 2 .

4. The host cell of claim 3 , wherein the host cell co-expresses N-acetylglucosamine-1-phosphoTransferase (GNPT).

5. The host cell of claim 4 , wherein the host cell comprises an exogenous nucleic acid encoding GNPT.

6. The host cell of claim 4 , wherein the host cell has activated expression of endogenous GNPT.

7. A method for producing a targeted therapeutic fusion protein, comprising:

a) culturing cells comprising a nucleic acid of claim 1 , wherein the cells co-express N-acetylglucosamine-1-phosphoTransferase (GNPT); and

b) recovering the fusion protein produced by the cells.

8. The nucleic acid of claim 1 , wherein the fusion protein comprises an amino acid sequence at least 90% identical to SEQ ID NO: 18.

9. The nucleic acid of claim 1 , wherein the fusion protein comprises an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO. 23.

10. The nucleic acid of claim 1 , wherein the lysosomal targeting moiety and the lysosomal enzyme is fused via a linker.

11. The nucleic acid of claim 10 , wherein the linker comprises a sequence of

(SEQ ID NO.: 15)

GAPGGGGGAAAAAGGGGGGAPGGGGGAAAAAGGGGGGAPGGGGGAAAAAG

GGGGGAP.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2021
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056420/0964 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2017
From: CONCINO, MICHAEL F.; STRACK-LOGUE, BETTINA; MEIYAPPAN, MUTHURAMAN; NORTON, ANGELA W.; ZHANG, BOHONG; ISKENDERIAN, ANDREA; LOW, LIEH YOON; LUNDBERG, DIANNA; ROMASHKO, ALLA; NAIMY, HICHAM
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 043145/0941 →
Continuity (2)
Provisional Application 62036082 · Aug 11, 2014
Related Publication 20170232076A1 · Aug 17, 2017
Cited By (3)
US 12,325,753 US 12,428,487 US 12,662,545